( 1995-2003)
Ai Kang Biotechnology (Hangzhou) Co., Ltd. has completed the construction of rapid immunoassay technology platform from its establishment to becoming a professional manufacturer of rapid diagnosis series products.
Ai Kang's global development strategy requires us to have a perfect quality management system, constantly enhance international competitiveness and ensure the company's sustained and rapid development. After 1998 was registered by FDA in the United States and 1999 was certified by GMP in China, Ai Kang gradually formed a competitive advantage with quality as its core competitiveness by virtue of its perfect quality management system and excellent product quality. Independent research and development, brand building
(2004-2008)
Ai Kang Company takes independent innovation as the main theme, increases investment in technology research and development, integrates the latest technologies in BT and IT fields, and constantly innovates and develops in high-tech fields such as molecular biological diagnostic reagents, biosensors and bioelectronics. , seized the commanding heights of the biological industry and became an industry leader in the field of rapid diagnosis and medical device segmentation.
R&D and technological innovation are the source of enterprise development, and the cross-development of biology and information technology will be the inevitable trend of future technological development. Ai Kang Company invested a lot of R&D personnel and R&D funds, and completed the construction of four technical platforms: rapid immunoassay platform, antigen-antibody technology platform, biosensor technology platform and rapid gene diagnosis technology platform, and successfully developed a variety of medical device products with independent intellectual property rights, such as monoclonal antibody diagnostic reagents, blood glucose detection systems and urine analysis systems.
Aikang people know that quality is the lifeline of success. With the perfect quality management system and excellent product quality, Aikang passed the on-site audit of the US FDA for the first time in 2005, and successfully passed the on-site audit of the US FDA again in 2008 with excellent results of "zero defects". The product quality meets the product certification standards of US Food and Drug Administration, European CE registration and US Food and Drug Administration 5 10K.
After years of brand building, Ai Kang has formed a perfect quality management system for product development, manufacturing, sales and service, and many products rank first in the domestic market share. Through the continuous and effective implementation, operation and maintenance of the quality management system, Ai Kang strictly controls all links from product design and development to product delivery, from raw material procurement to product after-sales service, so as to provide customers with more satisfactory products and services. Technological innovation, leading technology.
(2008-present)
Relying on the technical advantages of talents in China and the United States, Ai Kang has formed a perfect industrialization system of R&D, production and sales in the field of biological diagnosis, and has become a global provider of health products and services.
After successfully developing Apotheker series blood glucose meters, urine analyzers and other products, Aikang also introduced dry biochemical analyzers, hemoglobin analyzers, blood lipid analyzers and other medical devices and corresponding detection reagents. Every year, more than 20 kinds of diagnostic products, such as PCR detection reagents, enzyme-linked immunosorbent assay reagents and colloidal gold detection reagents, are listed, and the products sell well in more than 40 countries and regions around the world. It is one of the largest industrialization bases of biological diagnostic products in the world.